Teva declares commercial availability of QVAR RediHaler Inhalation Aerosol
Teva Pharmaceutical Industries asserted the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in both 40 mcg and 80 mcg strengths by prescription in the U.S QVAR RediHaler which is a breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
Dr. Warner W. Carr, MD, Associate Medical Director of Southern California Research at Allergy and Asthma Associates of Southern California Medical Group claimed “As a physician, it’s often a challenge to know if my patients are using their inhalers correctly once they leave the office. It’s reassuring to see new device technologies come to market, such as the QVAR RediHaler device, which is designed specifically to eliminate the need for hand-breath coordination.”
Stark differentiation is witnessed in QVAR RediHaler and cconventional metered-dose inhalers (MDIs) by extending medication via a breath-actuated inhaler, eliminating the need for hand-breath coordination during inhalation. QVAR RediHaler administers the same active ingredient found in previously available QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol, but utilizes innovative breath-actuated inhaler technology. QVAR RediHaler was also designed to be ready for use.
Brendan O’Grady, Executive Vice President, North America Commercial at Teva said “By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of QVAR RediHaler in the coming months.”
Teva plans to revoke sales of the previously available QVAR.